Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE

Nucl Med Rev Cent East Eur. 2022;25(2):136-137. doi: 10.5603/NMR.a2022.0030. Epub 2022 Jul 18.

Abstract

A 64 years-old woman with intestinal neuroendocrine tumor (NET) and multiple liver metastases was referred for peptide receptor radioligand therapy (PRRT) with [177Lu]Lu-DOTATATE. A few days after the third cycle of PRRT, erythema and swelling in the injection site is occurred which progressed up to one-month post-therapy. The cutaneous lesion was managed by a plastic surgeon with topical treatment. Amino acid extravasation could have devastating effects and should always be considered in patients who underwent PRRT and who receive amino acids for nephroprotection.

Keywords: NET; PRRT; [177Lu]Lu-DOTATATE; cutaneous; extravasation.

MeSH terms

  • Amino Acids
  • Female
  • Humans
  • Middle Aged
  • Neuroendocrine Tumors* / metabolism
  • Octreotide / therapeutic use
  • Organometallic Compounds* / adverse effects
  • Organometallic Compounds* / therapeutic use
  • Positron-Emission Tomography
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Receptors, Peptide / metabolism

Substances

  • Amino Acids
  • Organometallic Compounds
  • Radiopharmaceuticals
  • Receptors, Peptide
  • copper dotatate CU-64
  • Octreotide